DBV Technologies SA

DBV

Company Profile

  • Business description

    DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

  • Contact

    107 Avenue de la Republique
    Batiment IRO
    Chatillon
    Paris92320
    FRA

    T: +33 155427878

    E: [email protected]

    https://www.dbv-technologies.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    109

Stocks News & Analysis

stocks

Apple earnings: Strong iPhone beat brings our valuation up and tariff costs prove light for now

We think Apple stock looks fairly valued.
stocks

4 ASX shares that could be vulnerable to an August surprise

Any missteps this reporting season could be costly for these shares, which have all risen to lofty valuations.
stocks

Another incredible quarter from Microsoft

We were wrong when we thought last quarter would be hard to top.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,917.1081.90-0.91%
CAC 407,546.16225.81-2.91%
DAX 4023,425.97639.50-2.66%
Dow JONES (US)43,588.58542.40-1.23%
FTSE 1009,068.5864.23-0.70%
HKSE24,507.81265.52-1.07%
NASDAQ20,650.13472.31-2.24%
Nikkei 22540,799.60270.22-0.66%
NZX 50 Index12,706.7222.68-0.18%
S&P 5006,238.01101.38-1.60%
S&P/ASX 2008,662.0080.80-0.92%
SSE Composite Index3,559.9513.26-0.37%

Market Movers